Reunion Neuroscience Inc. to Participate in October Investor Conferences Post published:October 5, 2023 Post category:Press Release
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression Post published:September 18, 2023 Post category:Press Release
Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement Post published:August 1, 2023 Post category:Press Release
Reunion Neuroscience Inc. Obtains Final Court Order for ProposedĀ Plan of Arrangement Post published:July 14, 2023 Post category:Press Release
Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement Post published:July 13, 2023 Post category:Press Release
Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update Post published:June 29, 2023 Post category:Press Release
Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact Post published:June 1, 2023 Post category:Press Release
Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference Post published:April 25, 2023 Post category:Press Release
Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors Post published:April 3, 2023 Post category:Press Release
Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting Post published:March 27, 2023 Post category:Press Release